Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML

References

• HowladerNNooneAKrapchoM webpage on the InternetSEER Cancer Statistics Review, 1975–2014Bethesda, MDNational Cancer Institute2017 Available from: https://seer.cancer.gov/csr/1975_2014/Accessed April 25, 2018
   Google Scholar
• LancetJEUyGLCortesJEFinal results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AMLJ Clin Oncol20163415_suppl7000
   Web of Science ®Google Scholar
• PreislerHDAndersonKRaiKThe frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 yearsBr J Haematol19897121891942923805
   PubMed Web of Science ®Google Scholar
• RaiKRHollandJFGlidewellOJTreatment of acute myelocytic leukemia: a study by cancer and leukemia group BBlood1981586120312126946847
   PubMed Web of Science ®Google Scholar
• PreislerHDavisRBKirshnerJComparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B studyBlood1987695144114493552076
   PubMed Web of Science ®Google Scholar
• EsteyESmithTLKeatingMJMcCredieKBGehanEAFreireichEJPrediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemiaLeukemia1989342572632927176
   PubMed Web of Science ®Google Scholar
• VoglerWRVelez-GarciaEWeinerRSA phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group StudyJ Clin Oncol1992107110311111607916
   PubMed Web of Science ®Google Scholar
• FernandezHFSunZYaoXAnthracycline dose intensification in acute myeloid leukemiaN Engl J Med2009361261249125919776406
   PubMed Web of Science ®Google Scholar
• LowenbergBOssenkoppeleGJvan PuttenWHigh-dose daunorubicin in older patients with acute myeloid leukemiaN Engl J Med2009361131235124819776405
   PubMed Web of Science ®Google Scholar
• WeickJKKopeckyKJAppelbaumFRA randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group studyBlood1996888284128518874180
   PubMed Web of Science ®Google Scholar
• BishopJFMatthewsJPYoungGAA randomized study of high-dose cytarabine in induction in acute myeloid leukemiaBlood1996875171017178634416
   PubMed Web of Science ®Google Scholar
• BishopJFLowenthalRMJoshuaDEtoposide in acute nonlymphocytic leukemia. Australian Leukemia Study GroupBlood199075127322403818
   PubMed Web of Science ®Google Scholar
• BuchnerTHiddemannWWormannBDouble induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative GroupBlood199993124116412410361108
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGTambaroFPBekeleNBPhase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndromeJ Clin Oncol201230182204221022585696
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGOthusMPagelJMSWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (“7+3”) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML) Abstract #901Presented at: The 2016 ASH Annual MeetingSan Diego, USA2016
   Google Scholar
• StoneRMMandrekarSJSanfordBLMidostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutationN Engl J Med2017377545446428644114
   PubMed Web of Science ®Google Scholar
• SteinEMDiNardoCDPollyeaDAEnasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood201713072273128588020
   PubMed Web of Science ®Google Scholar
• BurnettAWetzlerMLowenbergBTherapeutic advances in acute myeloid leukemiaJ Clin Oncol201129548749421220605
   PubMed Web of Science ®Google Scholar
• BowerHAnderssonTMBjorkholmMDickmanPWLambertPCDerolfARContinued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of lifeBlood Cancer J20166e39026849011
   PubMed Web of Science ®Google Scholar
• AppelbaumFRGundackerHHeadDRAge and acute myeloid leukemiaBlood200610793481348516455952
   PubMed Web of Science ®Google Scholar
• LindsleyRCMarBGMazzolaEAcute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood201512591367137625550361
   PubMed Web of Science ®Google Scholar
• Granfeldt OstgardLSMedeirosBCSengelovHEpidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort studyJ Clin Oncol201533313641364926304885
   PubMed Web of Science ®Google Scholar
• DombretHSeymourJFButrymAInternational phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood2015126329129925987659
   PubMed Web of Science ®Google Scholar
• SorrorMLStorerBEElsawyMIntensive versus non-intensive induction therapy for patients (Pts) with newly diagnosed acute myeloid leukemia (AML) using two different novel prognostic modelsBlood2015128216
   Web of Science ®Google Scholar
• MayerLDHarasymTOTardiPGRatiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing miceMol Cancer Ther2006571854186316891472
   PubMed Web of Science ®Google Scholar
• LimWSTardiPGDos SantosNLeukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenograftsLeuk Res20103491214122320138667
   PubMed Web of Science ®Google Scholar
• KimHPGerhardBHarasymTOMayerLDHoggeDELiposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cellsExp Hematol201139774175021530609
   PubMed Web of Science ®Google Scholar
• GhobrialIMDetappeAAndersonKCSteensmaDPThe bone-marrow niche in MDS and MGUS: implications for AML and MMNat Rev Clin Oncol201815421923329311715
   PubMed Web of Science ®Google Scholar
• TardiPWanCPMayerLPassive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomesJ Drug Target201624979780427143215
   PubMed Web of Science ®Google Scholar
• FeldmanEJLancetJEKolitzJEFirst-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemiaJ Clin Oncol201129897998521282541
   PubMed Web of Science ®Google Scholar
• FeldmanEJKolitzJETrangJMPharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemiaLeuk Res201236101283128922840315
   PubMed Web of Science ®Google Scholar
• LancetJECortesJEHoggeDEPhase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLBlood2014123213239324624687088
   PubMed Web of Science ®Google Scholar
• LancetJEFeldmanEJCortesJEHoggeDETallmanMSCPX-351 in AML after failed induction with cytarabine and daunorubicinJ Clin Oncol201628no. 15_suppl6572
   Web of Science ®Google Scholar
• CortesJEGoldbergSLFeldmanEJPhase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AMLCancer201512123424225223583
   PubMed Web of Science ®Google Scholar
• LancetJERitchieEKUyGLEfficacy and safety of CPX-351 versus 7+3 in older adults with secondary acute myeloid leukemia: combined subgroup analysis of phase 2 and phase 3 studiesBlood20171302657
   Google Scholar
• UyGLLancetJECortesJEMultivariate efficacy analysis of a randomized, phase 3 study of CPX-351 versus 7+3 in older adults with treatment-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changesBlood20171302647
   Web of Science ®Google Scholar
• MedeirosBCLancetJECortesJERates of adverse events per patient-year in a randomized, phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, treatment-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changeBlood20171301366
   Google Scholar
• BanerjeeKWangQWangJGibbonsJCPX-351 exposure-response based on cumulative dose of cytarabine and daunorubicin in patients with newly diagnosed, treatment-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changesBlood20171301360
   Web of Science ®Google Scholar
• RoweJMLowenbergBGemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drugBlood2013121244838484123591788
   PubMed Web of Science ®Google Scholar
• CastaigneSPautasCTerreCEffect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studyLancet201237998251508151622482940
   PubMed Web of Science ®Google Scholar
• LinTLUyGLWieduwiltMJSubanalysis of patients with secondary acute myeloid leukemia (sAML) with refractory anemia with excess of blasts in transformation (RAEB-t) enrolled in a phase 3 study of CPX-351 versus conventional 7+3 cytarabine and daunorubicinBlood20171301698
   Web of Science ®Google Scholar